Science decoded, the business angle included.
Ingredient markets, clinical studies under scrutiny, regulatory, AI visibility. Every insight is sourced — PubMed, EFSA, dated reports — and ends with what it changes for your pipeline.
Insights — Page 2
Dairy matrix: why full-fat is coming off the bench
In brief — A University of Toronto trial (74 adults, 12 weeks, Journal of Nutrition, 2026) shows three daily servings of full-fat dairy worsen neither weight…
Read the insight
The AI Act and health content: the exception that saves your editorial line
In brief — Since 2 August 2026, Article 50 of Regulation (EU) 2024/1689 requires labelling AI-generated texts that inform the public.
Read the insight
Postbiotics, probiotics, prebiotics: what market?
In short — probiotics are live micro-organisms, prebiotics their substrates (fibres), and postbiotics the compounds derived from them.
Read the insight
Protein ingredients: moving beyond the gram wars
Protein ingredients aren't just about grams: quality, digestibility, food matrix and the complementarity of sources change everything.
Read the insight
Oat-based ingredients: 10% of LDL in 2 days
A study by the University of Bonn shows that high-dose oat-based ingredients reduce LDL by 10% via the gut microbiota.
Read the insight
China's Probiotics Market: 3 B2B Opportunities to Seize in 2026
China's Probiotics Market: 3 Actionable B2B Signals to Discover in 2026 — Stable Growth, Scientific Scrutiny, and Public Communication.
Read the insight
Precision microbiome: the ingredient opportunity in 2026
Precision microbiome: why the loss of microbial functions linked to modern life opens up an innovation space for pro- and prebiotics.
Read the insight
Calcium and vitamin D: science says no to universal supplementation, yes to nuance
Calcium and vitamin D: what does the science really say about supplementation? A review nuances the benefits and calls for personalised recommendations.
Read the insight
The AHA's 9 Cardiovascular Recommendations 2026
The AHA 2026 is restructuring its 9 cardiovascular priorities. Discover the direct implications for your ingredients and your B2B strategy.
Read the insight
Protein ingredients: what GLP-1 drugs are changing
Protein ingredients are gaining ground as a result of GLP-1 drugs: –21 % calories, +11 % protein. What this means for food R&D.
Read the insight
CMO's number 1 priority in 2026: Brand. AI decides who makes the shortlist.
In 2026, CMOs will rank the brand as priority number 1. In B2B food, AI will pre-select suppliers before the first contact. What this changes.
Read the insight
Plant-based or animal proteins: the source leaves a microbial footprint
Plant-based or animal-based proteins: a machine learning study shows that the source leaves a distinct microbial fingerprint, predicted with 88% accuracy.
Read the insight